Literature DB >> 11781610

Enumeration of bone marrow 'homing' haemopoietic stem cells from G-CSF-mobilised normal donors and influence on engraftment following allogeneic transplantation.

A Spencer1, J Jackson, C Baulch-Brown.   

Abstract

Expression of the chemokine receptor CXCR4 on human haemopoietic stem cells (HSC) may play a crucial role in localising these cells to the bone marrow. To evaluate whether CXCR4 expression is clinically relevant we have enumerated CXCR4-positive HSC used for allogeneic transplantation and sought any relationship with the rate of subsequent haemopoietic reconstitution. CD34-positive progenitor cells were isolated from peripheral blood stem cell (PBSC) collections from 16 normal donors. The proportion of cells co-expressing CXCR4 was enumerated and the times to recipient haemopoietic reconstitution measured. The median frequency of CD34-positive cells co-expressing CXCR4 was 41% (range 16% to 76%) and the median number of CXCR4 CD34 double-positive cells infused at transplantation was 2.5 x 10(6) cells/kg (range 0.8-10.3). Patients receiving >2.5 x 10(6) CXCR4 CD34 double-positive cells/kg demonstrated a significant shortening of time to platelet engraftment compared to the recipients of the lower cell doses (10 days vs 14.5 days, respectively, P = 0.02) with all but one of the recipients of the higher cell doses achieving platelet engraftment by day 11. Co-expression of CXCR4 on CD34-positive progenitor cells may be an important determinant of post-transplant engraftment and in our hands transplantation of a minimum of 2.5 x 10(6) CXCR4 CD34 double-positive cells/kg ensured rapid post-transplant platelet recovery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781610     DOI: 10.1038/sj.bmt.1703289

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Quality of long-term cryopreserved umbilical cord blood units for hematopoietic cell transplantation.

Authors:  Shohei Yamamoto; Hirokazu Ikeda; Daisuke Toyama; Mayumi Hayashi; Kousuke Akiyama; Manabu Suzuki; Yutaka Tanaka; Tsuneki Watanabe; Yoko Fujimoto; Ichirou Hosaki; Hirokazu Nishihira; Keiichi Isoyama
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

2.  A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.

Authors:  N Kurita; M Gosho; Y Yokoyama; T Kato; N Obara; M Sakata-Yanagimoto; Y Hasegawa; N Uchida; S Takahashi; Y Kouzai; Y Atsuta; M Kurata; T Ichinohe; S Chiba
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

3.  Cationic liposome-mediated CXCR4 gene delivery into hematopoietic stem/progenitor cells: implications for clinical transplantation and gene therapy.

Authors:  Hilal Gul-Uludag; Peng Xu; Leah A Marquez-Curtis; James Xing; Anna Janowska-Wieczorek; Jie Chen
Journal:  Stem Cells Dev       Date:  2011-12-14       Impact factor: 3.272

Review 4.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

Review 5.  Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.

Authors:  Arkadiusz Gzil; Izabela Zarębska; Wiktor Bursiewicz; Paulina Antosik; Dariusz Grzanka; Łukasz Szylberg
Journal:  Mol Biol Rep       Date:  2019-09-05       Impact factor: 2.316

Review 6.  Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Philip Smith; Catherine O'Sullivan; Peter Gergely
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

7.  The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.

Authors:  Hadrien Golay; Simona Jurkovic Mlakar; Vid Mlakar; Tiago Nava; Marc Ansari
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.